Craif and the National Cancer Center Hospital presented the analysis at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2025 (ASCO GI 2025) in San Francisco.
SAN FRANCISCO, February 26, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, presented a joint analysis of blood and urinary microRNA in pancreatic cancer with the National Cancer Center Hospital at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2025 (ASCO GI 2025), held January 23 to 25, 2025 in San Francisco. In 59 pancreatic cancer patients, the group identified two microRNAs in urine whose expression levels differed depending on whether the patient had cachexia. In serum from the same study, no microRNA differed by cachexia status.
The presentation, "Analysis of Blood and Urinary MicroRNA in Pancreatic Cancer with Cachexia," was given with Mao Okada and colleagues at the National Cancer Center Hospital.
This was a conference presentation.
Craif was founded in 2018 as a venture out of Nagoya University. Its platform, NANO IP (NANO Intelligence Platform), detects disease-related biomolecules, including microRNA, with high accuracy in easy-to-collect body fluids such as urine. Craif uses NANO IP to develop tests for early cancer detection and individualized care.
What the study found
- MicroRNA analysis can surface candidate cachexia biomarkers. The team extracted exosomes from serum and urine samples from 59 pancreatic cancer patients, 41 with cachexia and 18 without, and ran comprehensive microRNA profiling by next-generation sequencing. 141 microRNAs were common to serum and urine, 81 were specific to serum, and 33 were specific to urine.
- Urine separated the two groups where serum did not. In serum, microRNA expression levels did not differ by the presence or absence of cachexia. In urine, two microRNAs showed expression differences by cachexia status.
- Urinary microRNAs may help detect cachexia early.
The results suggest urinary microRNA could serve as a biomarker for early detection of the weight loss and muscle wasting of cachexia in pancreatic cancer patients. The researchers state that clinical use would first require explaining the mechanism by which differences absent in serum appeared in urine, and that the relationship between urinary microRNA and cachexia needs further study.
Why cachexia matters in pancreatic cancer
Cachexia, the subject of the study, is a complex metabolic disorder marked by loss of appetite, weight loss, and wasting of skeletal muscle. As it progresses, it affects physical function and the effect of chemotherapy, and it lowers quality of life. It is one of the leading causes of cancer-related death and is especially common in advanced pancreatic cancer. Preventing its progression depends on finding it early and starting treatment, but no effective biomarker for early detection of cachexia has been established. The study analyzed blood and urinary microRNAs by next-generation sequencing with the goal of early detection of cancer cachexia in pancreatic cancer patients.
The miSignal series is not a medical device. It determines risk by statistically analyzing the data. It does not replace a medical diagnosis of whether a person has cancer, and a low-risk result does not mean cancer is absent or that the person will not develop cancer in the future.
About ASCO GI 2025
- Dates: January 23 to 25, 2025
- Location: San Francisco, California
- Official website: https://conferences.asco.org/gi/
The Gastrointestinal Cancers Symposium is run by the American Society of Clinical Oncology and is commonly called ASCO GI.
About Craif
Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.
